Vapaliximab

Vapaliximab is a chimeric monoclonal antibody[1] and an experimental immunosuppressive drug. Development was discontinued by 2012.[2]

Vapaliximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
TargetVAP-1
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
 NY (what is this?)  (verify)

References
  1. WHO Drug Information
  2. "Vapaliximab - AdisInsight". adisinsight.springer.com. Retrieved 2 January 2019.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.